Semaglutide, a glucagon-like peptide (GLP)-1 agonist developed by Novo Nordisk, has demonstrated non-inferiority in cardiovascular (CV) risk, in fact,...
The unprecedented, 10-year, head-to-head trial to compare the effectiveness of active monitoring, surgery and radiotherapy in localized prostate cance...
In hormone receptor (HR)-positive, early breast cancer, the use of aromatase inhibitor (AI) is limited to five years only owing to the lack of efficac...
Immunotherapy with anti-PD-1 antibodies, Pembrolizumab (Keytruda, Merck & Co), was found to be superior to platinum-based doublet chemotherapy, th...
In just a week of time, a CD38 monoclonal antibody–daratumumab (Darzalex, Janssen)- has been reported twice to markedly reduce disease progression b...
The detailed findings of the study was presented on 5-June in 2016, by the lead investigator Alan P Venook, MD, professor of medicine at the Universit...
EMPA-REG OUTCOME trial was the first positive FDA-mandated cardiovascular (CV) outcome study for anti-hyperglycemia medicine reported last fall.1 Yet,...
This is the second FDA-mandated cardiovascular (CV) outcome study for anti-hyperglycemic medicine showing positive results after the EMPA-REG trial of...
FIT is a common modality for colorectal cancer (CRC) screening; positive tests require a follow-up diagnostic colonoscopy. However, little is known ab...
TAF is an investigational treatment (Gilead Sciences) for CHB while TDF is an approved treatment option and is one of the two guideline-recommended nu...
